tbuckley/cabot-search huggingface dataset:
연구논문 : 논평 참조 ; 만성 간질환에서 간탄성률 측정에 영향을 미치는 요인 분석
Authors: 이다미 ( Da Mi Lee ), 문은준 ( Eun Joon Moon ), 황주안 ( Joo An Hwang ), 이민석 ( Min Suk Lee ), 정재연 ( Jae Youn Cheong ), 조성원 ( Sung Won Cho ), 김영배 ( Yeong Bae Kim ), 김동준 ( Dong Joon Kim ), 황성규 ( Seong Gyu Hwang ), 양진모 ( Jin Mo Yang )
Journal: Clinical and Molecular Hepatology (2009)

목적: 본 논문은 만성 간질환 환자를 대상으로 간탄성률 측정에 영향을 미치는 요인을 알아보기 위해 연구를 시행하였다. 대상과 방법: Transient elastography와 간조직검사를 시행한 만성 간질환 환자 158명을 대상으로 혈액검사 및 간조직 소견을 분석하였으며, 간조직검사 결과는 대한병리학회 기준에 따라 0~4단계로 분류하였다. 결과: 간탄성률은 간조직생검으로 확인한 간섬유화 정도와 유의한 상관관계를 보였다(P=0.636. P<0.001). 간염의 소엽 내 활성도 및 문맥역/문맥주변부 활성도가 높아질수록 간탄성률 측정치도 증가하였으며, spearman 상관계수가 각각 0.359(P<0.001), 0.448(P<0.001)로 유의하였다. 또한 간탄성률은 혈청 총 빌리루빈치, 직접 빌리루빈치, GGT 수치, INR 등과 양의 상관관계가 있었으며, 혈청 알부민치 및 혈소판치와는 음의 상관관계가 있었다. 다변량 회귀분석에서는 간섬유화(B 3.50, P=0.009) 및 간염의 소엽 내 활성도(B 3.25, P=0.047)만이 간탄성률과 관련이 있는 것으로 나타났다. 결론: 만성 간질환 환자에서 간탄성률은 간섬유화뿐만 아니라 간내 염증 활성도에 의해서도 영향을 받음을 확인하였으며, 간탄성률의 해석에 간섬유화뿐만 아니라 간내 염증 정도도 고려해야 할 것이다.
Upconversion Luminescence Sandwich Assay For Detection of Influenza H7 Subtype
Authors: Ming‐Kiu Tsang, Yuen‐Ting Wong, Tik‐Hung Tsoi, Wing‐Tak Wong, Jianhua Hao
Journal: Advanced Healthcare Materials (2019)

Abstract With large anti‐Stokes shifts and background‐free signals, upconversion luminescent (UCL) screening assays have been a promising method to reduce the transmission of influenza epidemic, which can critically alleviate the disease burden and extra annual deaths. In this work, a luminescent resonance energy transfer sandwich assay is developed, which utilizes core–shell upconversion nanoparticles and gold nanoparticles as the donor and acceptor, respectively. The influenza H7 gene of H7N9 virus is used as the target for optimization of the assay. Importantly, the hybridization time of the assay is ≈40 min and the specificity test indicates the probes are specific toward the H7 target. The limit of detection of the system is ≈134 × 10 −12 m (≈3.22 × 10 10 molecules). Moreover, the assay is tested with the use of polymerase chain reaction validated samples from human isolates. The results are promising for implanting future on‐site rapid influenza screening application.
Occurrence of Cardiotoxicity and the Impact on Outcomes Among Children Treated on the AAML0531 Clinical Trial: A Report from the Children's Oncology Group
Authors: Kelly D Getz, Lillian Sung, Bonnie Ky, Robert B Gerbing, Kasey J Leger, Allison Barz, Leah Sack, William G Woods, Todd A Alonzo, Alan S Gamis, Richard Aplenc
Journal: Blood (2017)
Evaluation of a nonbiologic nanoparticle form of paclitaxel in metastatic pancreatic cancer.
Authors: Kouros Motamed, Larn Hwang, Chao Hsiao, Vuong N. Trieu
Journal: Journal of Clinical Oncology (2013)

e15076 Background: The (nab-Pac)/Gemcitabine (Gem) combination has recently been shown to impart a significant survival advantage over Gem alone in patients with metastatic pancreatic cancer. The goal of this study was to define a non-biologic, nanoparticle paclitaxel (NBN-Pac) which has a similar toxicity profile and utilizes the same albumin-mediated transport mechanism. Herein, we report in vitro, preclinical and phase I clinical results for this NBN-Pac in metastatic pancreatic cancer. Methods: In vitro drug cytotoxicity was measured as mean IC 50 values following a 72-h exposure in four pancreatic cell lines (MIA Paca-2 and Capan-1 and multi-drug resistant cell lines PANC-1 and ASPC-1). In vivo anti-tumor activities were assessed in xenografted MIA PaCa-2 and PANC-1 models in nude mice treated with three i.v. doses of NBN-Pac (20, 50 mg/kg) and Taxol (20 mg/kg) on days 0, 3, and 6 (q3dx3), and twelve i.v. doses of Gem (140 mg/kg) on every 3 days (q3dx12). A phase I clinical trial (N=18) was conducted to determine the MTD and the recommended phase II dose of the combination therapy with NBN-Pac (220-300 mg/m 2 , q3w) and Gem (1250 mg/m 2 ) as primary endpoints in first line treatment of subjects with advanced pancreatic cancer. Reduction in the plasma levels of CA19-9 was measured as a PD biomarker. Results: The mean IC 50 value of NBN-Pac in four pancreatic cell lines was approximately 30-fold lower than that of Gem. NBN-Pac formulation (50 mg/kg) produced superior anti-tumor activity in the two xenograft models tested over Taxol and Gem at clinically equivalent doses. Our phase I trial established the MTD of this NBN-Pac formulation as 300mg/m 2 . Moreover, 5 out of 16 subjects (31.3%) were CR or PR with 95% exact confidence interval of (11.0%, 58.7%). The median PFS time was 5.6 month (95% C.I = 2.9). The median OS time could not be estimated as the survival rate did not fall below 50%. Other safety variables revealed no significant abnormality that may have affected the result of the study. Conclusions: NBN-Paclitaxel formulation has superior anti-tumor activity vs. Taxol and Gem in in vitro toxicity assays, preclinical models of pancreatic cancer, as well in a phase I clinical study in patients with advanced pancreatic cancer.
A survival-based cost-effectiveness analysis of 5 years of letrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer: 76-month update of BIG-1–98
Authors: J. Karnon, S. Kaura
Journal: Journal of Clinical Oncology (2009)

6566 Background: The latest update of the BIG 1–98 study reports a hazard ratio for overall survival (OS) of 0.81 (95% CI 0.69 = 0.94) (censoring TAM patients who crossed over to LET). Previous economic analyses of the aromatase inhibitors extrapolated observed differences in time to recurrence. This study uses observed differences in OS to estimate the incremental cost per life year (LY), and per quality adjusted LY (QALY) gained of 5 years LET versus 5 years TAM in ER+ postmenopausal women, from a UK NHS perspective. Methods: Annual survival probabilities over the first 7 years post-surgery were extracted from updated BIG 1–98 results. Survival was extrapolated to 20 years using data reported by the Early Breast Cancer Trialists’ Group for women receiving 5 years TAM. Equivalent annual survival probabilities were assumed for the LET and TAM groups post-7 years (likely to be a conservative assumption given diverging OS between 5 and 7 years). Costs included those of the interventions and and a wide range of adverse events (AEs). Published five year costs for locoregional recurrence (LR) and metastases (METS) were applied to reported recurrence rates over 9 years. A Markov model applied published utility weights for DFS with AEs, LR, and METS. All costs and health benefits were discounted at 3.5% annually. Results: The reference case results show that over a 20 year period, the discounted additional treatment costs of LET'are £4,427, and AEs incur an additional £88 per patient, while the reduced frequency decreases the cost difference by £807. The total cost difference between LET and TAM is £3,707. The discounted gain in LYs is 0.286. The incremental cost per LY gained for LET over TAM is £12,970. The Markov model estimated a difference in discounted QALYs of 0.297, with an incremental cost per QALY gained of £12,500. Conclusions: The economic analysis of 5 years LET compared to 5 years TAM based on observed differences in OS produces similar results to earlier modelled extrapolations based on differences in time to recurrence. However, the 20 year time horizon used in this analysis is shorter than previous analyses, and so the results may be considered conservative, i.e. LET may be more cost-effective than previously estimated. [Table: see text]
Medicine in the Fourth Dimension
Authors: Christopher R. Cederroth, Urs Albrecht, Joseph Bass, Steven A. Brown, Jonas Dyhrfjeld-Johnsen, Frederic Gachon, Carla B. Green, Michael H. Hastings, Charlotte Helfrich-Förster, John B. Hogenesch, Francis Lévi, Andrew Loudon, Gabriella B. Lundkvist, Johanna H. Meijer, Michael Rosbash, Joseph S. Takahashi, Michael Young, Barbara Canlon
Journal: Cell Metabolism (2019)
Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west
Authors: Jian Lu, Xiu-Ping Zhang, Bin-Yan Zhong, Wan Yee Lau, David C Madoff, Jon C Davidson, Xiaolong Qi, Shu-Qun Cheng, Gao-Jun Teng
Journal: The Lancet. Gastroenterology & hepatology (2019)
A retrospective study of dose-dense adjuvant paclitaxel without G-CSF support in patients with breast cancer.
Authors: Anurag Kumar Singh, Akshiv Malhotra, Sheila M. Lemke
Journal: Journal of Clinical Oncology (2013)

e20547 Background: Dose dense AC (Adriamycin plus Cyclophosphamide) followed by paclitaxel (Pac) given every 2 weeks with Granulocyte-Colony Stimulating factor (G-CSF) support remains the standard of care for adjuvant chemotherapy in newly diagnosed breast cancer patients . Although, the need for growth factor support with AC is clear, its role with dose dense Pac is not so clear. The objective of this retrospective single institution study was to evaluate the need for primary prophylaxis with G-CSF with dose dense Pac. Methods: Data from 115 patients treated at Upstate Medical University from 2005-2012 was collected after IRB approval. All patients received four cycles of dose dense AC (A- 60mg/m2 with C- 600 mg/m2) with G-CSF support on day 2 followed by Pac (175 mg/m2) with no primary G-CSF support. The median age of patients was 48 years. There were 11 patients (10%) with Stage I, 68 (60%) with stage II and 36 (30%) with stage III disease. The prevalence of ER/HER2 status was as follows: ER+/Her2 + (13%), ER+/Her2-(60%), triple negative (26%) and ER-/Her2+ (1%). Results: Only 3 patients (2.6%) in this study population developed neutropenic fever. 109 patients received no G-CSF support and completed a total of 382 doses of Pac (average 3.5). Dose reduction was needed in 6 patients, related to neutropenic fever (n=3), neutropenia without fever (n=2) and severe arthralgia (n=1). A total of 88 patients completed all planned four cycles. Of the 27 patients who got less than the planned 4 cycles, most stopped because of neuropathy (n=17), arthralgia (n=4), hand foot syndrome (n=2), elevated LFTs (n=1), allergic reaction (n=1) and unknown reason (n=1). Most common Grade III/IV toxicity was neuropathy. Dose delays were seen in only 5 patients, 3 related to neutropenia and 2 because of elevated liver function tests. Conclusions: G-CSF has its own side effects, most common being bone pain. G-CSF also adds significantly to climbing costs of oncology care. Although retrospective in nature, this study shows that only a small minority of the patients develop neutropenic complications with dose-dense Pac. Avoiding primary prophylaxis with G-CSF will not only reduce costs but also reduce toxicity that can be additive to Pac toxicity.
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
Authors: Farhad Ravandi, Rita Assi, Naval Daver, Christopher B Benton, Tapan Kadia, Philip A Thompson, Gautam Borthakur, Yesid Alvarado, Elias J Jabbour, Marina Konopleva, Koichi Takahashi, Steven Kornblau, Courtney D DiNardo, Zeev Estrov, Wilmer Flores, Sreyashi Basu, James Allison, Padmanee Sharma, Sherry Pierce, Allison Pike, Jorge E Cortes, Guillermo Garcia-Manero, Hagop M Kantarjian
Journal: The Lancet Haematology (2019)
Clinicians wanting to engage with research should join an ethics committee
Authors: Simon E Kolstoe
Journal: BMJ (2019)

Maben and King discuss the opportunities and barriers for NHS staff wanting to take part in research.1 One positive aspect of the prolonged process required to gain grant funding and necessary project approval is that it forces potential researchers to be explicit about what they want to do, how they plan to do it, and whether their results are likely to be useful. Although this painful process …
Circulating miR-337-3p as a novel biomarker for prostate cancer.
Authors: Manuel Valladares Ayerbes, Vanessa Medina Villaamil, Sara Martinez Breijo, Isabel Santamarina Cainzos, Guadalupe Aparicio, Jose Gonzalez Dacal, Paula Portela Pereira, Dario Vazquez Pazos, Francisco Gomez-Veiga, Luis M. Antón Aparicio
Journal: Journal of Clinical Oncology (2013)

5087 Background: Recent studies have demonstrated that the aberrant expression of microRNAs (miRNAs)is related with the development of prostate cancer (PCa). Detection of circulating tumor cells (CTC) may provide diagnostic and prognostic information inPCa. The purpose is identifying circulating miRNAs potentially useful for CTC detection in patients with PCa. Methods: In the first study phase we examined blood levels of 92 miRNAs in 49 patients grouped in pools by risk classification: low-risk 42.8%, intermediate-risk 22.5% and high-risk 34.7% and healthy volunteers (N=10) using SYBR-green-based microARN RT-qPCR arrays (Exiqon). Prostate cancer diagnosis was obtained by transrectalultrasound guided biopsy of 10 cores, PSA and digital rectal examination was done previously. In the second study phase using quantitative real-time polymerase chain reaction (qPCR) by TaqMan Human MicroRNAAssays (Life Technologies), we compared the expression levels of miRNAs in blood samples from 34 patients of low-risk, 31 of intermediate-risk, 18 of high-risk localized disease and 22 healthy volunteers paired by age with cases. Receiver-operator characteristic (ROC) curve was used. Results: Blood samples from patients with low, intermediate, high-risk and healthy controls exhibit distinct circulating miRNA signatures. microRNAsdifferential expressed between risk groups (p&lt;0.01) (low, intermediate and high) and control group: 0microARNs upregulated (MU), 12 MU and 68 MU respectively. Highlight the significantlyoverexpression in the intermediate risk group and maintained at the high-risk of microRNAs: 337-3p[247 PicTar predictions (PTP)], 330-3p (307 PTP) and 218 (551 PTP). Preliminary results of the second study phase showed that the median level of miRNA,337-3p was significantly higher in patients with high-risk than that in healthy controls (p=.001). ROC curve analyses indicated that this blood miRNA may beuseful for discriminating patients with high-risk from healthy controls (AUC=.724). Conclusions: miRNAs in the circulation are relatively stable, very accessible, low invasive and easily testable biomarkers. Our preliminary promisingresults suggest miR-337-3p as novel stable blood-based marker for PCa detection.
Abstract 436: Targeting Fatty Acid Oxidation by Acetyl-CoA Carboxylase 2 Deletion in Pathological Hypertrophy
Authors: Julia Ritterhoff, Outi Villet, Stephen C Kolwicz, Dan Shao, Rong Tian
Journal: Circulation Research (2017)

We have previously shown that preserving fatty acid oxidation (FAO) by cardiac-specific deletion of Acetyl-CoA Carboxylase 2 (ACC2) prevents the shift of substrate preference towards glucose, reduces cardiomyocyte hypertrophy and preserves cardiac function during chronic pressure overload. To determine whether maintaining FAO specifically prevented cardiomyocyte hypertrophy, we treated adult rat cardiomyocytes (CMs) with and without adenoviral-mediated ACC2 knock-down (KD) with phenylephrine (PE, 10 μM). ACC2 KD effectively prevented CM hypertrophy after PE stimulation compared to control CMs (+9±6% vs. 42±6%) in medium supplemented with fatty acids (FA) (5.5 mM glucose, 0.4 mM mixed long-chain FAs and 0.1 mU/ml insulin). Whereas PE stimulation in control CMs increased glucose uptake (+28±8%) this was normalized after ACC2 KD. Inhibiting FAO by etomoxir or increasing glucose utilization by dichloroacetate abolished the beneficial effects of ACC2 KD after PE stimulation. When cultured in glucose-free medium supplemented with FA, ACC2 KD was incapable of preventing cardiomyocyte hypertrophy. However, replacing glucose with pyruvate or propionate restored the anti-hypertrophic effect of ACC2 KD. To determine the therapeutic effects of increasing FAO in vivo , male mice were subjected to transverse aortic constriction (TAC) and sham surgery. Three weeks after surgery, TAC mice had a significant increase in left ventricular (LV) mass as determined by echocardiography compared to sham operated mice (130 vs. 92 mg). At this time point, cardiac-specific ACC2 deletion (iKO) was induced by tamoxifen (tam) administration. ACC2 protein was effectively deleted in iKO sham and TAC hearts compared to controls (CON) 2 weeks post tam injection. FAO was 2-fold higher in iKO TAC vs. CON TAC hearts as assessed by isolated heart perfusion and 13C NMR spectroscopy. CON and iKO mice will be followed until 12 weeks after TAC to determine cardiac function and assess hypertrophy. Together, these data indicate that increasing FAO via inactivation of ACC2 exerts anti-hypertrophic effect in adult cardiomyocytes. Deleting ACC2 in the hypertrophic heart in vivo can increase FAO and represents a valid target to treat pathological cardiac hypertrophy.
Abstract 118: GPR68, a proton-sensing GPCR that mediates interaction of pancreatic cancer associated fibroblasts and cancer cells, is a potential therapeutic target for pancreatic cancer
Authors: Shu Z. Wiley, Krishna Sriram, Cristina Salmeron-Salvador, Hiroshi Nishihara, Randall French, Andrew M. Lowy, Paul A. Insel
Journal: Cancer Research (2019)

Abstract Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense fibrotic stroma (desmoplasia) that is generated by pancreatic cancer associated fibroblasts (PCAFs) derived from pancreatic stellate cells (PSCs) and pancreatic fibroblasts (PFs). We discovered that GPR68, a proton-sensing GPCR, has much higher expression in PCAFs compared to either PFs or PSCs. GPR68 activation in PCAFs enhances interleukin-6 (IL-6) expression via a cAMP/PKA/CREB signaling pathway. GPR68 knockdown with siRNA decreased low pH-induced IL-6 production by PCAFs and increased the proliferation of PDAC cells by PCAF conditioned media. Ogerin, a GPR68 positive allosteric modulator, enhanced the pH-dependent increase in cAMP in PCAFs. A pilot screening of 96 GPCR-specific compounds tested with GPR68-overexpressing HEK293 cells identified two compounds (C1 and C2) that decrease intracellular cAMP at pH6.4, but not isoproterenol (β-adrenergic receptor)-induced cAMP, implying their selective antagonism of GPR68. Furthermore, compound C2 decreased low pH-induced IL-6 levels in the conditioned media of GPR68-overexpressing HEK293 cells We conclude that GPR68 in PCAFs detects low pH, contributes to PDAC cell-PCAF interaction and may be a novel therapeutic target for pancreatic cancer. Note: This abstract was not presented at the meeting. Citation Format: Shu Z. Wiley, Krishna Sriram, Cristina Salmeron-Salvador, Hiroshi Nishihara, Randall French, Andrew M. Lowy, Paul A. Insel. GPR68, a proton-sensing GPCR that mediates interaction of pancreatic cancer associated fibroblasts and cancer cells, is a potential therapeutic target for pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 118.
“Tidal flow variability measured by impedance pneumography relates to childhood asthma risk.” Ville-Pekka Seppä, Anna S. Pelkonen, Anne Kotaniemi-Syrjänen, Jari Viik, Mika J. Mäkelä and L. Pekka Malmberg. <i>Eur Respir J</i> 2016; 47: 1687–1696.
Authors: Ville-Pekka Seppä, Anna Pelkonen, Anne Kotaniemi-Syrjänen, Jari Viik, Mika Mäkelä, L Pekka, Malmberg Eur
Journal: European Respiratory Journal (2016)
Return to primary service among bone marrow transplant rehabilitation inpatients: An index for predicting outcomes.
Authors: Jack Brian Fu, Jay Ted Lee, Dennis Wesley Smith
Journal: Journal of Clinical Oncology (2012)

e19509 Background: Inpatient rehabilitation bone marrow transplant patients can be challenging due to their medical fragility. Methods: One hundred forty-seven bone marrow transplant patients admitted to inpatient rehabilitation at a major national cancer hospital between January 1, 2002, and April 15, 2009, regardless of the patient’s primary cancer were retrospectively studied. Return to primary service and factors including age, gender, race, presence of graft-versus-host disease, type of hematopoietic stem cell transplant, type of primary cancer, white blood cell count upon rehabilitation admission, platelet count, albumin level, prealbumin level, creatinine level, and presence of antimicrobial agents were analyzed. Results: Forty-one percent (61/147) of bone marrow transplant patients were transferred from the inpatient rehabilitation unit back to the primary service. Of those transferred back, 38% died after being transferred back to the primary service; 53%, 36%, and 39% of leukemia, lymphoma, and multiple myeloma transplant patients were transferred back to the primary service, respectively. No breast, germinoma, renal, testicular, or Waldenstrom macroglobulinemia patients were transferred back to primary service. Significant relationships were found with a platelet count &lt; 43 (p&lt;.01), a creatinine level &gt; 0.9 (p&lt;.05), the presence of an antibacterial agent (p&lt;.05), the presence of an antifungal agent (p&lt;.05) and leukemia, lymphoma or multiple myeloma type (p&lt;.05). Using these 4 of these factors the Fu index was formulated to determine the likelihood of return to the primary team. Conclusions: Bone marrow transplant patients have a high rate of transfer from the inpatient rehabilitation unit back to the primary service and many of them eventually died while in the hospital. A low platelet count, a high creatinine level, the presence of an antibacterial agent, and the presence of an antifungal agent significantly increased the risk of return to primary. Close follow-up by the primary team while on the inpatient rehabilitation unit is recommended.
Athlete monitoring: a complementary prevention strategy for groin and hamstring injuries in elite football (PhD Academy Award)
Authors: Martin Wollin
Journal: British Journal of Sports Medicine (2019)

I devised, implemented and investigated athlete monitoring as a complementary prevention strategy for groin and hamstring injuries in professional development football. The aim was to introduce a novel system based on primary, secondary and tertiary prevention for groin and hamstring injuries. I investigated the potential of secondary prevention in football, which relies on knowledge of postmatch recovery responses of groin and hamstring function.

Groin and hamstring injuries are common in football and can impact player development and team performance.1 2 Despite growing knowledge and detail of these injuries, current prevention approaches have not changed the reported incidence and burden.3 4 In this context, alternative and complementary prevention systems are warranted.

I performed five original studies. Studies 1 and 2 investigated the responses of clinical groin tests in-season and during match congestion. Study 1 …